Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium, 1200
- Neurocrine Clinical Site
-
Ghent, Belgium, 9000
- Neurocrine Clinical Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1C9
- Neurocrine Clinical Site
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- Neurocrine Clinical Site
-
-
Quebec
-
Montréal, Quebec, Canada, H3T 1C5
- Neurocrine Clinical Site
-
-
-
-
-
Angers, France, 49933
- Neurocrine Clinical Site
-
Bordeau, France, 33076
- Neurocrine Clinical Site
-
Le Kremlin-Bicêtre, France, 94270
- Neurocrine Clinical Site
-
Paris, France, 75015
- Neurocrine Clinical Site
-
Paris, France, 75019
- Neurocrine Clinical Site
-
-
-
-
-
Berlin, Germany, 13353
- Neurocrine Clinical Site
-
Heidelberg, Germany, 69120
- Neurocrine Clinical Site
-
Magdeburg, Germany, 39120
- Neurocrine Clinical Site
-
-
-
-
-
Athens, Greece, 115 27
- Neurocrine Clinical Site
-
Athens, Greece, 11527
- Neurocrine Clinical Site
-
-
-
-
-
Bologna, Italy, 40138
- Neurocrine Clinical Site
-
Milan, Italy, 20132
- Neurocrine Clinical Site
-
Napoli, Italy, 80131
- Neurocrine Clinical Site
-
Roma, Italy, 00165
- Neurocrine Clinical Site
-
-
-
-
-
Gdańsk, Poland, 80-214
- Neurocrine Clinical Site
-
Rzeszów, Poland, 35-301
- Neurocrine Clinical Site
-
-
-
-
-
Barcelona, Spain, 08035
- Neurocrine Clinical Site
-
Sevilla, Spain, 41013
- Neurocrine Clinical Site
-
-
-
-
-
London, United Kingdom, WC1N 3JH
- Neurocrine Clinical Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Neurocrine Clinical Site
-
-
California
-
Los Angeles, California, United States, 90027
- Neurocrine Clinical Site
-
Orange, California, United States, 92868
- Neurocrine Clinical Site
-
San Diego, California, United States, 92123
- Neurocrine Clinical Site
-
San Francisco, California, United States, 94158
- Neurocrine Clinical Site
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Neurocrine Clinical Site
-
-
Connecticut
-
Hartford, Connecticut, United States, 06106
- Neurocrine Clinical Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Neurocrine Clinical Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Neurocrine Clinical Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Neurocrine Clinical Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Neurocrine Clinical Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Neurocrine Clinical Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55454
- Neurocrine Clinical Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63104
- Neurocrine Clinical Site
-
-
New York
-
New Hyde Park, New York, United States, 11040
- Neurocrine Clinical Site
-
New York, New York, United States, 10065
- Neurocrine Clinical Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Neurocrine Clinical Site
-
Tulsa, Oklahoma, United States, 74135
- Neurocrine Clinical Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Neurocrine Clinical Site
-
Pittsburgh, Pennsylvania, United States, 15224
- Neurocrine Clinical Site
-
-
Texas
-
Dallas, Texas, United States, 75235
- Neurocrine Clinical Site
-
-
Washington
-
Seattle, Washington, United States, 98105
- Neurocrine Clinical Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be willing and able to adhere to the study procedures, including all requirements at the study center, and return for the follow-up visit.
- Have a medically confirmed diagnosis of classic CAH due to 21-hydroxylase deficiency.
- Be on a stable steroid regimen.
- Have elevated androgen levels.
- Participants of childbearing potential must be abstinent or agree to use appropriate birth control during the study.
Exclusion Criteria:
- Have a diagnosis of any of the other forms of classic CAH.
- Have a history of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic glucocorticoid therapy.
- Have a clinically significant unstable medical condition or chronic disease other than CAH.
- Have a history of cancer unless considered to be cured.
- Have a known history of clinically significant arrhythmia or abnormalities on electrocardiogram (ECG).
- Have a known hypersensitivity to any corticotropin-releasing hormone antagonist.
- Have received an investigational drug within 30 days before initial screening or plan to use an investigational drug (other than the study drug) during the study.
- Have current substance dependence or substance (drug) or alcohol abuse.
- Have had a significant blood loss or donated blood or blood products within 8 weeks prior to the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Crinecerfont
Crinecerfont solution or capsule, administered orally, twice daily for 28 weeks during the placebo-controlled treatment period, followed by active treatment with crinecerfont for at least 24 weeks.
|
CRF type 1 receptor antagonist
Other Names:
|
|
Placebo Comparator: Placebo
Placebo solution or capsule, administered orally, twice daily for 28 weeks, followed by active treatment with crinecerfont for at least 24 weeks.
|
Non-active dosage form
CRF type 1 receptor antagonist
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Serum Androstenedione at Week 4
Time Frame: Baseline, Week 4
|
Blood serum samples were collected for the analysis of serum androstenedione concentrations.
Least square (LS) mean and standard error (SE) were calculated using analysis of covariance (ANCOVA) model.
|
Baseline, Week 4
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change From Baseline in Serum 17-hydroxyprogesterone (17-OHP) at Week 4
Time Frame: Baseline, Week 4
|
Baseline, Week 4
|
|
Percent Change From Baseline in Glucocorticoid Daily Dose at Week 28
Time Frame: Baseline, Week 28
|
Baseline, Week 28
|
|
Number of Participants Who Achieved a Reduction to Physiologic Glucocorticoid Dose While Maintaining Androstenedione Control at Week 28
Time Frame: Week 28
|
Week 28
|
|
Change From Baseline in Body Mass Index (BMI) Standard Deviation Score (SDS) at Week 28
Time Frame: Baseline, Week 28
|
Baseline, Week 28
|
|
Change From Baseline in Mean 24-hour Salivary 17-OHP at Week 28
Time Frame: Baseline, Week 28
|
Baseline, Week 28
|
|
Change From Baseline in the Ratio of Bone Age to Chronological Age (BA:CA) at Week 28
Time Frame: Baseline, Week 28
|
Baseline, Week 28
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Development Lead, Neurocrine Biosciences
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Endocrine System Diseases
- Pathologic Processes
- Male Urogenital Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Gonadal Disorders
- Congenital Abnormalities
- Adrenal Gland Diseases
- Disorders of Sex Development
- Urogenital Abnormalities
- Steroid Metabolism, Inborn Errors
- Hyperplasia
- Adrenal Hyperplasia, Congenital
- Adrenogenital Syndrome
- Adrenocortical Hyperfunction
Other Study ID Numbers
Other Study ID Numbers
- NBI-74788-CAH2006
- 2020-004381-19 (EudraCT Number)
- 2023-509170-33-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.